HIV/AIDS HAART
Racivir safe and effective in HAART-naive HIV-infected patients
Published in AIDS Weekly, September 12th, 2005
"Racivir [RCV; (±)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine], a 50:50 racemic mixture of the two P nucleoside enantiomers, is currently in development for the treatment of human immunodeficiency virus type I (HIV-1) infections.
"RCV was administered once a day orally for 14 days at doses of 200, 400, or 600 mg in combination with stavudine and efavirenz to HIV-1-infected treatment-naive male volunteers in a phase Ib/IIa study," scientists writing in the journal Antimicrobial Agents and Chemotherapy report.
"Six volunteers at each dose were...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-09-12)
More Articles from AIDS Weekly
- HIV/AIDS Diagnostics
HIV-1 RNA from dried-blood spot samples correlates with plasma viral load - HIV/AIDS Exposure
CD91 expression increased on monocytes of exposed/HIV-1-seronegative subjects - HIV/AIDS Postexposure Prophylaxis
HIV postexposure prophylaxis not routinely offered following sexual assault - HIV/AIDS Research
Biological assay system demonstrates human retroviral protease activity - HIV/AIDS Screening
HIV infection detected in emergency department screening in low prevalence area - Angiosarcoma
Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
